Skip to main content

Table 1 Patient, tumour characteristics and disease stages for 53 breast cancers on 50 patients

From: Phase I-II study of hypofractionated simultaneous integrated boost using volumetric modulated arc therapy for adjuvant radiation therapy in breast cancer patients: a report of feasibility and early toxicity results in the first 50 treatments

Age [years]

Median

68

 

Range

36-88

T

pT1mi

1 (2%)

 

pT1a

6 (11%)

 

pT1b

11 (21%)

 

pT1c

20 (38%)

 

pT2

15 (28%)

N

pN0

49 (92%)

 

pN1

4 (8%)

Histology

IDC

41 (77%)

 

ILC

10 (19%)

 

Other Invasive

2 (4%)

 

DCIS

0 (0%)

Grading

I

10 (19%)

 

II

38 (72%)

 

III

5 (9%)

Estrogen Receptors

Positive

49 (92%)

 

Negative

4 (8%)

Progesterone Receptors

Positive

46 (87%)

 

Negative

7 (13%)

Her-2/neu

Overexpressed

1 (2%)

 

Not overexp.

52 (98%)

Ki-67

≥20

3 (6%)

 

<20

50 (94%)

Disease Stage

0

0 (0%)

 

I

43 (81%)

 

II

10 (19%)

  1. IDC: invasive ductal carcinoma; ILC: invasive lobular carcinoma; DCIS: ductal carcinoma in situ.